An interventional study of LASER Lithotripsy ( Fragmentation modality) and LASER lithotripsy (Dusting Modality) in Ureteric Stone, sponsored by District Headquarters Teaching Hospital Sahiwal. Completed at 1 site in Pakistan. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by District Headquarters Teaching Hospital Sahiwal · Not applicable, Interventional, and Treatment
Ureteroscopic laser lithotripsy is becoming the most commonly utilized treatment for patients with ureteral stone. The Holmium: YAG laser is integral to the operation and is the preferred flexible intracorporeal lithotripsy. It is considered cost-effective and efficient choice in ureteroscopic lithotripsy on all types of stones. As in recent years, there has been increasing interest in examining the effect of varying the laser settings on the effectiveness of stone treatment. The objective of the study is to compare the fragmentation and dusting modalities utilizing Holmium YAG laser in ureteroscopy for ureteral stone treatment. It will be a randomized control trial (RCT) in which 160 patients visiting Sahiwal Teaching Hospital, Sahiwal will be included. The patients will be divided into two groups. Group-A patients will be treated with fragmentation modality utilizing Holmium YAG laser while Group-B patients will be treated with dusting modality utilizing Holmium YAG laser. Simple random sampling technique will be carried out. The patients' age, gender, stone number, stone laterality, stone location, ureteral condition, reteropulsion, stricture formation, stone clearance, operative time, hospital stay, presence of retropulsion and complications will be recorded. Data will be collected through proforma, which will be entered and analyzed using SPSS version 26.0. For quantitative variables such as: age, operation time, hospital stay, stone number ,mean and standard deviation will be calculated and for qualitative variables such as: gender, and laterality, stone location, ureter condition, prevalence of pyuria, stone clearance, presence of retropulsion, ureter injury, frequency and percentages will be calculated. Data will be presented in tables and graphs for both quantitative and qualitative variables. Chi-square test will be used to estimate the association between study variables. P-value \<0.05 will be considered significant. It is anticipated that the results of this study will be helpful for health care planners and surgeons to provide better treatment option to the patients with ureteral stone.
Exclusion Criteria:
Group A patients will be treated with fragmentation modality utilizing Holmium YAG laser.
Procedure: LASER Lithotripsy ( Fragmentation modality)
Group B patients will be treated with dusting modality utilizing Holmium YAG laser.
Procedure: LASER lithotripsy (Dusting Modality)
Group-A patients will be treated with fragmentation modality utilizing Holmium YAG laser.
Group-B patients will be treated with dusting modality utilizing Holmium YAG laser.
Stone Free Rate
Stone-free will be defined as no residual stones \> 3 mm in the ureter of the affected side at one month postoperatively on computerized tomography (CT KUB Plain).
Time frame: There would be 4 follow up visits. First visit will be after 1 week of URSL and X Ray KUB will be done. Second visit will be after 2 weeks of URSL and we will plan the removal of DJ stent. Those cases in which ureteral inury is suspected or stone burden
Reteropulstion
Retropulsion, defined as unintended migration of stone into the kidney, leads to failure and results in a lower SFR.
Time frame: During procedure.
Uretral Stricture Formation
Post-URS ureteral stricture is defined as complete or partial ureteral obstruction as shown by the excretory phase of CTU, which was confirmed with delayed or absent radioactive tracer washout at 8 weeks after stent removal.
Time frame: Post-URS ureteral stricture is defined as complete or partial ureteral obstruction as shown by the excretory phase of CTU, which was confirmed with delayed or absent radioactive tracer washout at 8 weeks after stent removal.
Plan to share: No
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
District Headquarters Teaching Hospital Sahiwal